Oncolytics Biotech Reports Updated Anal Cancer Data
Oncolytics Biotech Inc. announced updated results from the GOBLET study, showing that pelareorep plus atezolizumab achieves a 30% objective response rate (ORR) in second-line or later squamous cell anal carcinoma (SCAC) patients.
This compares to a 13.8% ORR for the current FDA-approved second-line treatment. The median duration of response was 15.5 months, compared to 9.5 months for the standard of care.
Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment
The company expects to discuss a single-arm accelerated approval study with the FDA in Q1 2026.
Author's summary: Oncolytics Biotech reports promising anal cancer data.
More News
- Ehlmann Announces Reelection Bid for St. Charles County Executive in 2026 - The Missouri Times
- Donald Trump endorses Republican Jeff Hurd's bid for reelection bid in Colorado's 3rd CD
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- 9 Black Actresses Who Went From Broadway To The Hollywood Big Screen
- Bitcoin Miner TeraWulf (WULF) Stock Jumps 25% On AI News
- Families fish, bond at Trees Lake event - News
- Users aren't happy with Copilot AI taking over the Microsoft 365 app
- Randomly-textured lithium niobate gives snapshot spectrometer a boost – Physics World
- A Wake-Up Call for Iran’s Banking System